Insider buying last 90 days
No open-market insider purchases were filed for KMTS in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every KMTS insider filing, plotted on the chart in Gekko.Open KMTS in Gekko
NASDAQ: KMTS
Kestra Medical Technologies (KMTS) Stock Analysis & Forecast
Oct 12 close
$26.91−0.07 (−0.3%)
Gekko Brief
AI summaryOct 12 closeThis week's coverage of Kestra Medical Technologies (KMTS) centers on comparative and valuation framing rather than new corporate news. One piece contrasts KMTS with Bioventus (BVS) across valuation, risk, dividends, institutional ownership and analyst recommendations, while another describes KMTS as modestly undervalued at $27.10 against a cited fair value of $30, tied to expectations for increased adoption of its cardiac wearables. No new earnings, guidance, deal or regulatory items appear in this week's headlines.
KMTS closed at $26.91, down 0.3%, sitting above both its 50-day average of $26.24 and its 200-day average of $23.59, with the 50-day above the 200-day. The stock's one-month return is 17.8% and its six-month return is 43.4%, within a 52-week range of $17.34 to $30. The GekkoIndex reads 56.5, placing it in the Neutral zone, up 4.7 over five sessions. Gekko Fair Value stands at $27.81, putting the current price 3.2% below that mark.
Kestra's next earnings report is scheduled for 10 December 2026, after the close, 58 days out and beyond a typical 20-trading-day hold. Its last reported quarter showed an actual EPS of -0.4 against an estimate of -0.6, with a -7.5% reaction, and the average absolute reaction across recent quarters is 7.7%. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Analyst coverage from 7 firms shows 6 buy and 1 hold ratings, with a consensus target of $30.29.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Kestra Medical Technologies price vs fair value
Close $26.91200-day averageGekko Fair Value $27.81
Kestra Medical Technologies quick facts
- Market cap
- $1.58B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.67
- Revenue, TTM
- $106.7M
- Profit margin
- -140.4%
- Dividend yield
- —
- Beta
- —
- Volume
- 131,009 avg 410,010
- 1-year return
- +14.6%
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±9.3%
- 50-day average
- $26.24
- 200-day average
- $23.59
- Next earnings
- Dec 10 after close
- Shares outstanding
- 59.56M
Kestra Medical Technologies swing-trade checklist
Kestra Medical Technologies scores 2 supportive, 2 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $26.91 is above the 50-day ($26.24) and 200-day ($23.59) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
56.5, Neutral
Reading 56.5 is in the Neutral zone.
See the GekkoIndex - Fair valuemixed
3.2% below
Price is within 5% of Gekko Fair Value (3.2% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 59 days
Next report Dec 10, 2026, 59 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Kestra Medical Technologies stock chart and price history
Kestra Medical Technologies closed at $26.91 on Oct 12, 2026, +14.6% over the past year, inside a 52-week range of $17.34 to $30.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +17.8%
- 3 months
- +11.3%
- 6 months
- +43.4%
- 1 year
- +14.6%
The full KMTS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open KMTS in Gekko
Follow Kestra Medical Technologies through every session
Put KMTS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track KMTS in GekkoFree for 7 days. No credit card required.
About Kestra Medical Technologies
Kestra Medical Technologies works at the crossroads of wearable devices and digital health, focusing on helping people with cardiovascular disease through connected monitoring and treatment tools. Its main product is the Cardiac Recovery System, a platform that brings together heart monitoring, active therapy, digital features, and support for patients in one package. Within this system sits the ASSURE WCD, a wearable defibrillator built for those facing a heightened chance of sudden cardiac arrest.
Beyond the physical device, the Cardiac Recovery System includes digital tools and services meant to keep patients and their healthcare providers connected and informed, with the aim of supporting better health outcomes over time.
Kestra Medical Technologies was established in 2014 and is based in Kirkland, Washington. Its shares are listed on the NASDAQ under the ticker KMTS.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- kestramedical.com
Kestra Medical Technologies GekkoIndex: the smart money zone
Kestra Medical Technologies’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.5, in the Neutral zone, up 4.7 points over five sessions.
56.5Neutral
Up 4.7 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 28 | +2.5% | +1.7% | ||
| Accumulation | 121 | +2.1% | +4.8% | ||
| Neutral (current zone) | 229 | −0.2% | +1.0% | ||
| Distribution | 14 | −1.7% | −4.8% | ||
| Selling | 5 | Too few readings yet | |||
Average KMTS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the KMTS price, zone by zone.Track KMTS in Gekko
Is Kestra Medical Technologies stock overvalued? Gekko Fair Value
Kestra Medical Technologies trades 3.2% below Gekko Fair Value of $27.81, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Kestra Medical Technologies shares are worth, recalculated every trading day.
$27.81
Gekko Fair Value, Oct 10, 2026
3.2% below fair value · About fair value
At the end of Aug 2026 the price was 9.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open KMTS in Gekko
Kestra Medical Technologies insider and Congress trading
No open-market insider purchases were filed for Kestra Medical Technologies, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in KMTS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for KMTS, plotted on the chart in Gekko.Open KMTS in Gekko
Buybacks
Kestra Medical Technologies has been buying back its own shares.
- Bought back, year ended Apr 30, 2026
- $2.79M
- As a share of market cap
- 0.18%
From company filings.
Hedge funds and billionaires quarter ended Sep 30
0of the funds Gekko tracks hold KMTS.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Kestra Medical Technologies earnings: next date and track record
Kestra Medical Technologies reports on Dec 10, 2026, after the close (59 days away), and beat the EPS estimate in 2 of its last 5 reports.
Next earnings report
Dec 10, 2026
Expected after the close, 59 days away
- EPS estimate
- −$0.61
- Revenue estimate
- $32.03M
2 of 5reports beat the EPS estimate
±7.7%average move across the report
2 of 5reports followed by a gain
Share-price move across each report
Last earnings call, Mar 18, 2026 AI summary
- What they said
- KEStra Medical Technologies reported strong Q3 fiscal 2026 results driven by robust revenue growth, improving gross margins, and operational progress. Revenue was $24.6M, up 63% year-over-year, with gross margin expanding to 52.6% (nine consecutive quarters of sequential improvement). Management highlighted product and clinical momentum (ACE PAS study results and an FDA-cleared algorithm update), a strategic collaboration and $5.0M equity investment in BioBeat to integrate ambulatory blood pressure monitoring, expanded commercial coverage (targeting ~130 territories by April), and important market-access wins (Florida managed Medicaid approvals and inclusion on the VA Federal Supply Schedule). The company raised FY2026 revenue guidance to $93.0M (from $91.0M prior), reiterated a path to 70%+ gross margins over the coming years, and reported a cash balance of $291M following a December equity offering. Operating expenses and adjusted EBITDA losses widened as the company invested in commercial expansion and public-company costs; cash burn included a meaningful CapEx investment in the quarter. Management emphasized durable long-term opportunity while noting execution, reimbursement, and guideline-related drivers required to materially expand the WCD market.
- Guidance
- Updated fiscal year 2026 revenue guidance increased to $93,000,000 (representing ~55% growth vs FY2025). Management also reiterated a multi-year objective to achieve 70%+ gross margins. No FY2027 numeric guidance was provided.
- Risks flagged
- Continued operating losses and negative adjusted EBITDA; meaningful cash burn driven by CapEx and operating investments; execution risk scaling the salesforce and integrating new territories; dependence on bringing many payers in-network (long tail of ~3,000 payers); competitive pressure from an entrenched incumbent (ZOLL) and potential product rollouts; need for clinical guideline changes to materially expand market adoption; seasonality and insurance plan-year effects that can depress conversion in certain quarters; regulatory and clinical risks associated with product updates and adoption.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 18, 2026 | −$0.40 est −$0.60 | $24.55M est $22.87M | −7.5% |
| Dec 11, 2025 | −$0.64 est −$0.57 | $22.57M est $22.87M | +6.7% |
| Sep 12, 2025 | −$0.50 est −$0.78 | $19.37M est $20.73M | +23.3% |
| Jul 15, 2025 | −$1.06 est −$0.53 | $17.23M | −0.5% |
| Apr 14, 2025 | −$1.18 est −$0.64 | — | −0.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Kestra Medical Technologies stock forecast and analyst price targets
Analysts’ average 12-month price target for Kestra Medical Technologies is $30.29, +12.6% from the last close, from 7 firms rating the stock in the last 90 days.
$30.29consensus 12-month target, +12.6% from the last close
Now $26.91Avg $30.29
Low $28High $32
Each firm’s latest rating in the last 90 days: 7 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 5 | Piper Sandler | $30 | +11.5% |
| Sep 15 | Piper Sandler | $30 | +11.5% |
| Sep 15 | BTIG | $32 | +18.9% |
| Sep 15 | Stifel Nicolaus | $30 | +11.5% |
| Sep 14 | Bank of America Securities | $30 | +11.5% |
+1.0%average 20-day move after past Neutral readings
±5.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Kestra Medical Technologies market cap and key statistics
Kestra Medical Technologies’s market cap is $1.58B and revenue of $106.7M over the last twelve months.
Valuation
- Market cap
- $1.58B
- EPS, TTM
- −$2.67
- Gekko Fair Value
- $27.81
Trading
- Volume
- 131,009
- Avg volume, 20 days
- 410,010
- 52-week high
- $30.00
- 52-week low
- $17.34
- Shares outstanding
- 59.56M
Financials
- Revenue, TTM
- $106.7M
- Profit margin
- -140.4%
- Return on equity
- -73.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±9.3%
Kestra Medical Technologies stock news this week
2 headlines about Kestra Medical Technologies from the past week, newest first, each linking to the publisher.
- Comparing Kestra Medical Technologies (NASDAQ:KMTS) & Bioventus (NASDAQ:BVS)Defense World, Oct 12
- Is Kestra Medical Technologies (KMTS) Undervalued Or Is Its Premium Already Priced In?Simply Wall Street, Oct 7
Kestra Medical Technologies peers
Kestra Medical Technologies’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 18.2% above |
| ABTAbbott Laboratories | Neutral | 14.7% below |
| DHRDanaher | Neutral | 4.5% above |
| ISRGIntuitive Surgical | Neutral | 18.8% above |
| MDTMedtronic | Neutral | 22.9% below |
| SYKStryker | Accumulation | 12.6% below |
A peer links to its own page where one exists.
Kestra Medical Technologies stock FAQ
What is Kestra Medical Technologies’s market cap?
Kestra Medical Technologies’s market cap is $1.58B at the Oct 12, 2026 close of $26.91, with 59.56M shares outstanding.
What is the Kestra Medical Technologies stock forecast?
The consensus analyst 12-month price target for Kestra Medical Technologies is $30.29, +12.6% from the last close. Of the 7 firms that rated the stock in the last 90 days, 6 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Kestra Medical Technologies stock overvalued or undervalued?
On Gekko’s estimate Kestra Medical Technologies is about fair value: the Oct 12, 2026 close of $26.91 is 3.2% below Gekko Fair Value of $27.81. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Kestra Medical Technologies report earnings next?
Kestra Medical Technologies is expected to report on Dec 10, 2026, after the market closes (59 days away). Analysts expect earnings of −$0.61 per share on revenue of $32.03M. Kestra Medical Technologies beat the earnings estimate in 2 of its last 5 reports, moving 7.7% on average across the report.
What is Kestra Medical Technologies’s 52-week high and low?
Kestra Medical Technologies’s 52-week high is $30.00 and its 52-week low is $17.34; it closed at $26.91 on Oct 12, 2026, +14.6% over the past year.
Is Kestra Medical Technologies stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 4 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Kestra Medical Technologies the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.